Switzerland· 65335001
Kengrexal 50mg, poudre pour solution à diluer pour solution injectable/pour perfusion
A cangrelor product containing cangrelorum, registered in Switzerland by Chiesi SA and dispensed under Swissmedic category B. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Cangrelor is registered in 13 of 19 countries.
Countries holding a registration under ATC B01AC25 (cangrelor), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Cangrelor · ATC B01AC25
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- cangrelorum
- Manufacturer
- Chiesi SA
- Country
- Switzerland (CH)
- ATC code
- B01AC25
- ATC class
- Cangrelor
- Defined daily dose
- 50 mg, P
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
135 interactions on record for cangrelor.
Graded by severity as the source publishes them — 65 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cangrelor · interactions on record
135 records
- 65 severe
- 70 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cangrelor in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKENGREXALChiesi Farmaceutici S.p.A., Parma
- SpainKENGREXAL 50 MG POLVO PARA CONCENTRADO PARA SOLUCION INYECTABLE Y PARA PERFUSIONChiesi Farmaceutici S.P.A.
- IcelandKengrexalChiesi Farmaceutici S.p.A.*
- PolandKengrexalChiesi Farmaceutici S.p.A.
- United StatesCangrelorGland Pharma Limited
- United KingdomKengrexal 50mg powder for concentrate for solution for injection / infusion vialsChiesi Ltd
- FranceKENGREXAL 50 mg, poudre pour solution à diluer pour solution injectable/pour perfusionCHIESI FARMACEUTICI
- CanadaKENGREXALCHIESI FARMACEUTICI S.P.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b27ee5df-fe85-482f-9d55-ae9038b9bc97 GET /v1/drugs/b27ee5df-fe85-482f-9d55-ae9038b9bc97?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about cangrelor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.